Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.59 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 9/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 2/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4208913 | 1.00 | BACE1 (0.59) | BACE1BACE2KISS1RCTSDOPRD1 | |
| SCHEMBL30262993 | 0.94 | KISS1R (0.55) | BACE1BACE2KISS1ROPRD1NPY4R | |
| SCHEMBL1525876 | 0.92 | BACE1 (0.64) | BACE1BACE2KISS1RCTSDNPY4R | |
| SCHEMBL18670433 | 0.92 | BACE1 (0.64) | BACE1BACE2KISS1RCTSDNPY4R | |
| SCHEMBL30931573 | 0.91 | OPRD1 (0.53) | KISS1ROPRD1NPY4RNPY1RNPY2R | |
| SCHEMBL29457312 | 0.90 | KISS1R (0.50) | BACE1BACE2KISS1RNPY4RNPY1R | |
| SCHEMBL29397496 | 0.90 | BACE1 (0.63) | BACE1BACE2KISS1ROPRD1NPY4R | |
| SCHEMBL30558097 | 0.89 | KISS1R (0.52) | KISS1ROPRD1NPY4RNPY1RNPY2R | |
| SCHEMBL34471860 | 0.89 | BACE1 (0.67) | BACE1BACE2KISS1RCTSDNPY4R | |
| SCHEMBL29897578 | 0.88 | KISS1R (0.54) | KISS1ROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250271443-A1 | SOLUBLE SINGLE-CHAIN DIMERS FROM CLEAVABLE SINGLE CHAIN TRIMERS | INSTITUTE FOR SYSTEMS BIOLOGY (US) | 2025-08-28 | — | — | US | claimed |
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | claimed |
| US-11999802-B2 | Compositions and methods for selective protein degradation | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | claimed |
| CN-116262911-A | Attenuated and replication-controllable forward HSV tracing system and construction method and application thereof | 中国科学院深圳先进技术研究院 | 2023-06-16 | — | — | CN | claimed |
| CN-114456276-A | Preparation method and application of long-acting exenatide | 中国科学院大学宁波华美医院 | 2022-05-10 | — | — | CN | claimed |
| US-20250271443-A1 | SOLUBLE SINGLE-CHAIN DIMERS FROM CLEAVABLE SINGLE CHAIN TRIMERS | INSTITUTE FOR SYSTEMS BIOLOGY (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250270290-A1 | RECOMBINANT TYPE-I HUMANIZED COLLAGEN POLYPEPTIDE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANXI JINBO BIO-PHARMACEUTICAL CO., LTD. (CN) | 2025-08-28 | — | — | US | disclosed |
| CN-120136999-A | Preparation method and application of label-free jewfish FGF2 recombinant protein | 中国海洋大学 | 2025-06-13 | — | — | CN | disclosed |
| CN-119799681-A | Recombinant TEV protease, recombinant vector and expression purification method | 浙江玉安康瑞生物科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-12270124-B2 | Method for screening protease variant and obtained protease variant | SHANGRAO CONCORD PHARMACEUTICAL CO., LTD (CN) | 2025-04-08 | — | — | US | disclosed |
| CN-119736283-A | TEV protease mutant and preparation method and application thereof | 深圳瑞德林生物技术有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119552229-A | Method for separating and purifying recombinant protein A in large scale with high loading capacity | 苏州赛分科技股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-7569660-B1 | Recombinant prion-like proteins and materials comprising same | THE UNIVERSITY OF CHICAGO (US) | 2009-08-04 | — | — | US | disclosed |
| US-20060105320-A1 | Electrical conductors and devices from prion-like proteins | THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2006-05-18 | — | — | US | disclosed |
| WO-2005118633-A2 | ELECTRICAL CONDUCTORS AND DEVICES FROM PRION-LIKE PROTEINS | THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050266242-A1 | Electrical conductors and devices from prion-like proteins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-01 | — | — | US | disclosed |
| US-20050227322-A1 | Recombinant prion-like genes and proteins and materials and methods comprising the same | LINDQUIST SUSAN | 2005-10-13 | — | — | US | disclosed |
| EP-1187920-A2 | RECOMBINANT PRION-LIKE GENES AND PROTEINS AND MATERIALS AND METHODS COMPRISING SAME | ARCH DEVELOPMENT CORPORATION (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000075324-A9 | RECOMBINANT PRION-LIKE GENES AND PROTEINS AND MATERIALS AND METHODS COMPRISING SAME | ARCH DEV CORP (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2000075324-A2 | RECOMBINANT PRION-LIKE GENES AND PROTEINS AND MATERIALS AND METHODS COMPRISING SAME | ARCH DEVELOPMENT CORPORATION (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | CRBN, RPS27A, COPB1 | BACE1 1841/4885BACE2 1575/4885KISS1R 4121/4885 |
| US-11999802-B2 | Compositions and methods for selective protein degradation | CRBN, RPS27A, COPB1 | BACE1 1841/4885BACE2 1575/4885KISS1R 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.